Comprehensive Evaluation and Management for a 61-Year-Old with Chronic Alcohol Use History
This patient requires immediate screening for alcohol use disorder (AUD) using the AUDIT questionnaire, assessment for alcohol-related liver disease (ALD) with liver function tests and non-invasive fibrosis evaluation, and implementation of brief motivational interventions combined with pharmacotherapy if alcohol dependence is confirmed.
Initial Screening and Assessment
Alcohol Use Disorder Screening
- Use the AUDIT (Alcohol Use Disorders Identification Test) as the gold standard screening tool 1
- Ask specifically about heavy drinking days per week and quantity consumed 2
- Document current drinking pattern: grams of alcohol per day (>30 g/day in men indicates risk for ALD) 3
Liver Disease Evaluation
All patients with chronic alcohol history require assessment for ALD, even if asymptomatic 3. The evaluation should include:
Liver function tests: AST, ALT, GGT, bilirubin, albumin, INR
Non-invasive fibrosis assessment (recommended as first-line) 4:
Risk stratification: Calculate MELD score if cirrhosis suspected 5
Additional Critical Assessments
- Screen for hepatitis B, hepatitis C, and HIV (synergistic liver damage with alcohol) 6
- Assess for metabolic syndrome, obesity, diabetes (accelerate ALD progression) 4
- Evaluate for cognitive impairment (high prevalence in chronic alcohol use) 4
- Screen for smoking (increases fibrosis and HCC risk) 4
- Check for nutritional deficiencies, particularly thiamine 6
Management Strategy Based on Findings
For All Patients with Chronic Alcohol History
1. Brief Motivational Intervention (MANDATORY) Brief interventions reduce alcohol consumption by an average of 57 g per week in men and decrease alcohol-related morbidity and mortality 1, 3. Use the "5 As" model 1:
- Ask about alcohol use
- Advise to quit or reduce
- Assess willingness to change
- Assist with strategies to quit/reduce
- Arrange follow-up
Add motivational interviewing techniques: empathic, non-judgmental, collaborative approach that respects patient autonomy 1, 3
2. Abstinence Counseling
- For any stage of ALD: Total abstinence is the most effective recommendation 1
- For compensated cirrhosis: 5-year survival is 90% with abstinence vs <70% with continued drinking 6
- For decompensated cirrhosis: 5-year survival is 60% with abstinence vs 30% with continued drinking 6
- Even low-level continued drinking (>2 drinks/day) significantly increases mortality in cirrhosis 4
Pharmacotherapy for Alcohol Dependence
Selection depends on liver disease severity:
For patients WITHOUT advanced liver disease (no cirrhosis or compensated cirrhosis):
Naltrexone 25 mg for 1-3 days, then 50 mg daily for 3-12 months 6
Acamprosate 1,998 mg/day (or 1,332 mg if <60 kg body weight) for 3-6 months 6
Disulfiram: Not commonly recommended due to poor tolerability and potential hepatotoxicity 5, 6
For patients WITH advanced liver disease (decompensated cirrhosis):
- Baclofen is the ONLY medication proven safe and effective in advanced ALD 1, 3
- Dose: Up to 80 mg/day 4, 3
- Use more gradual dose escalation in severe liver disease 4
- Increases abstinence and prevents relapse in cirrhotic patients 3, 6
All pharmacotherapy must be combined with counseling and psychosocial support 1
Management of Alcohol Withdrawal Syndrome (if present)
Benzodiazepines are the treatment of choice 1, 4:
- Long-acting (chlordiazepoxide 25-100 mg q4-6h, diazepam 5-10 mg q6-8h) for most patients 6
- Intermediate-acting (lorazepam 1-4 mg q4-8h) preferred for:
- Advanced liver disease
- Elderly patients
- Respiratory compromise 6
In decompensated cirrhosis: Use symptom-adapted dosing with short-acting agents only when necessary (>70% of cirrhotic patients don't require benzodiazepines) 4
Thiamine 100-300 mg/day for all patients with AWS to prevent Wernicke encephalopathy 6
Disease-Specific Management
If Alcoholic Fatty Liver (steatosis only):
- Total abstinence can achieve full recovery 6
- Continued drinking ≥400 g/week: 30% progress to cirrhosis, 37% to fibrosis/cirrhosis 6
If Compensated Cirrhosis:
- Refer for liver transplant evaluation if Child-Pugh C or MELD-Na ≥21 7
- HCC surveillance: ultrasound every 6 months (1% annual HCC risk) 6
- Manage portal hypertension complications per standard protocols
If Decompensated Cirrhosis:
- Urgent hepatology referral
- Liver transplant evaluation (abstinence duration should NOT be sole criterion) 7
- Aggressive management of ascites, encephalopathy, variceal bleeding
If Severe Alcoholic Hepatitis (jaundice, coagulopathy, recent heavy drinking):
- Calculate Maddrey Discriminant Function and MELD score 5
- If MDF ≥32 or MELD ≥21: Consider corticosteroids and/or early liver transplant 8, 7
- Nutritional support critical: goal >21.5 kcal/kg/day 8
Follow-Up Structure
Intensive initial phase (first 2-4 weeks):
- Multiple consultations to address uncertainties
- Ensure treatment adherence
- Initiate behavioral changes 9
Consolidation phase (months 1-6):
- Monthly visits 9
- Monitor liver function tests
- Reinforce abstinence/reduction goals
- Adjust pharmacotherapy as needed
Maintenance phase (after 6-12 months):
- Regular ongoing monitoring (frequency based on disease severity)
- Continued psychosocial support
- Screen for relapse 9
Critical Pitfalls to Avoid
- Do not rely solely on patient-reported drinking history - use validated screening tools (AUDIT) 1
- Do not prescribe naltrexone in advanced liver disease - use baclofen instead 1, 4
- Do not use APRI score for fibrosis assessment in ALD - it's unreliable 4
- Do not over-prescribe benzodiazepines in cirrhosis - most don't need them 4
- Do not delay liver transplant referral waiting for arbitrary abstinence periods 7
- Do not forget thiamine before giving IV glucose (precipitates acute deficiency) 6
- Do not assume low-level drinking is safe in established cirrhosis - even >2 drinks/day increases mortality 4